Biofrontera Inc.

NASDAQ (USD): Biofrontera Inc. (BFRI)

Last Price

1.23

Today's Change

+0.296 (31.69%)

Day's Change

0.795 - 2.21

Trading Volume

131,613,694

Profile
BFRI

Exchange:  NASDAQ Capital Market NASDAQ Capital Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Dr. Hermann Luebbert Ph.D. Dr. Hermann Luebbert Ph.D.

Full Time Employees:  83 83

IPO Date:  2021-10-29 2021-10-29

CIK:  0001858685 0001858685

ISIN:  US09077D2099 US09077D2099

CUSIP:  09077D100 09077D100

Beta:  0.51 0.51

Last Dividend:  0.00 0.00

Dcf Diff:  0.00 0.00

Dcf:  0.00 0.00

Description

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Address

120 Presidential Way,
Woburn, MA 01801, US

781 245 1325

http://www.biofrontera.us.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment